Amniotics granted key U.S. patent for PulmoStem™


August 10, 2022

Amniotics (publ) (Nasdaq Stockholm: AMNI) announced today that the US Patent and Trademark Office (USPTO) has approved a patent application for the company’s stem cell product PulmoStem™. This newly allowed U.S. patent, with application no. 17/646539, “Use of term amniotic fluid cells for the treatment of acute and chronic respiratory disease”, provides Amniotics with exclusive commercial rights in the U.S. at least until 2040 for the use of the amniotic derived stem cell product PulmoStem™ in the treatment of Acute Respiratory Distress Syndrome (ARDS).

Amniotics stem cell product PulmoStem™ is expected to be efficacious in various acute and chronic diseases of the lung through modulation of the immune response and anti-fibrotic capabilities. The first clinical study to commence this summer is targeting hospitalized patients suffering from respiratory tract infections due to COVID-19 and other causes, which can cause ARDS.

“This is the first U.S. patent granted in Amniotics patent portfolio and it confirms that our stem cell products and production methods are patentable, novel, and innovative. This approval also validates our long-term IP strategy, matching high quality patent applications with Amniotics products, ensuring market exclusivity for Amniotics technology. This is a great milestone, reached via a team effort, and I want to take the opportunity to thank our founders, inventors, and external consultants including our corporate patent advisor Dominic Davies and our US IP partner Knobbe Martens”, says Kåre Engkilde, CEO at Amniotics

Upcoming events

Read more